Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
erfonrilimab
- Development stage
- Phase 3
- Lead developer
- AlphaMab Oncology
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Erfonrilimab (KN046) is an investigational bispecific monoclonal antibody developed by Jiangsu Alphamab Biopharmaceuticals. It is designed to simultaneously target and block two key immune checkpoint pathways: Programmed Death-Ligand 1 (PD-L1) and Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4). By dual-targeting these receptors, erfonrilimab aims to restore and enhance the anti-tumor activity of T cells while potentially offering a more favorable safety profile compared to combinations of separate PD-(L)1 and CTLA-4 inhibitors. It is currently being evaluated in Phase II and Phase III clinical trials for various solid tumors, including non-small cell lung cancer (NSCLC), esophageal squamous cell carcinoma, and, in combination with the HER2-targeted bispecific antibody KN026, for HER2-positive solid tumors such as gastric and breast cancers.
- Other names
- erfonrilimab
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on erfonrilimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on erfonrilimab.